A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand
Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or
sores on the top layer of the skin which if left untreated can progress to skin cancer.
Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long
treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus
being researched.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs); and Local Skin Responses (LSR)
57 days
Yes
Janice Drew
Study Director
Peplin
United States: Food and Drug Administration
PEP005-018
NCT00544297
October 2007
January 2008
Name | Location |
---|---|
Dermatology Associates of Tyler | Tyler, Texas 75703 |
Skin Surgery Medical Group Inc | 5222 Balboa Avenue Sixth Floor San Diego, California 92117 |
Gwinnett Clinical Research Centre | 2383 Pate St, Snellville, Georgia 30078-3250 |
Dermatology Clinical Research Centre of San Antonio | 7810 Louis Pasteur Dr Suite 200 San Antonio, Texas 78229-3409 |